KẾT QUẢ ĐIỀU TRỊ NGƯỜI BỆNH NHIỄM HCV ĐƯỢC ĐIỀU TRỊ THUỐC KHÁNG VI RÚT TRỰC TIẾP (DAAs) TẠI VIỆN Y HỌC NHIỆT ĐỚI BẠCH MAI

Abstract

Objective: To describe the treatment outcomes of patients with hepatitis C virus (HCV) infection treated with direct-acting antivirals (DAAs) at the Bach Mai Institute of Tropical Medicine, Bach Mai Hospital. Subjects: Sixty-five patients diagnosed with HCV infection and treated at the Institute of Tropical Medicine, Bach Mai Hospital, who received direct-acting antiviral therapy with Sofosbuvir/Velpatasvir from July 2017 to September 2025, were selected using convenience sampling. Methods: A retrospective descriptive study. Results and conclusions: Male patients accounted for 66,2%, with a mean age of 49,1 years. The mean AST level after 4 weeks of treatment was 31,5 U/L, and 78,2% of patients had AST levels <40 U/L. After 12 weeks of treatment, the mean AST level was 26,6 U/L, and 90,3% of patients had AST levels <40 U/L. At 3–6 months after treatment completion, the mean AST level was 26,7 U/L, with a maximum value of 48 U/L, and 94,7% of patients had AST levels <40 U/L. The mean ALT level after 4 weeks of treatment was 33,2 U/L, and 78,2% of patients had ALT levels <40 U/L. After 12 weeks of treatment, the mean ALT level was 22,3 U/L, and 92,2% of patients had ALT levels <40 U/L. At 3–6 months after treatment completion, the mean ALT level was 21,5 U/L, with a maximum value of 67 U/L, and 94,7% of patients had ALT levels <40 U/L. After 4 weeks of DAAs treatment, 76,8% of patients had HCV-RNA levels below the limit of detection, while 23,2% had detectable HCV-RNA; among these, 20,9% had HCV-RNA levels <3 log IU/mL. The rate of sustained virologic response (SVR) at 12 weeks after treatment was 100% (n=65), and the SVR rate at 3–6 months after treatment completion was also 100% (n=18).